Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
07 Septembre 2023 - 10:01PM
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage
immuno-oncology company, today announced that Thomas Zindrick,
President, Chairman and CEO, will present a corporate overview with
institutional investors during the H.C. Wainwright 25th Annual
Global Investment Conference held the week of September 11th, 2023.
The Company will also attend virtual one-on-one
meetings during the conference. Institutional investors interested
in arranging a meeting with Genelux management can register to
attend the conference virtually or contact
genelux@allelecomms.com.
About Genelux
CorporationGenelux is a late clinical-stage
biopharmaceutical company focused on developing a pipeline of
next-generation oncolytic immunotherapies for patients suffering
from aggressive and/or difficult-to-treat solid tumor types. The
Company's most advanced product candidate, Olvi-Vec (olvimulogene
nanivacirepvec), is a proprietary, modified strain of the vaccinia
virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a
multi-center, randomized, open-label Phase 3 registrational trial
evaluating the efficacy and safety of Olvi-Vec in combination with
platinum-doublet + bevacizumab compared to platinum-doublet +
bevacizumab in patients with platinum-resistant/refractory ovarian
cancer. The core of Genelux's discovery and development efforts
revolves around the Company's proprietary CHOICE™ platform from
which the Company has developed an extensive library of isolated
and engineered oncolytic vaccinia virus immunotherapeutic product
candidates, including Olvi-Vec. For more information, please visit
www.genelux.com and follow us on Twitter @Genelux_Corp and on
LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MDAllele Communications,
LLCgenelux@allelecomms.com
Source: Genelux Corporation
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024